BusinessWeek Says " Why Cheaper Insulin Today Risks Higher Costs Later " . We should want that!

On April 4, 2023,Bloomberg BusinessWeek magazine published an article entitled " Why Cheaper Insulin Today Risks Higher Costs Later " (seehttps://www.bloomberg.com/news/articles/2023-04-04/cheaper-insulin-from-lilly-and-sanofi-risks-raising-costs-later for the article). Unfortunately, Americans have grown much too accustomed to seeing prescription drug prices being artificially manipulated from behind-the-scenes by entities who rig the system to line their own pockets that today, we instinctively view higher prices in the future as a direct assault. Don ' t play that game!But if the market was working properly to begin with, then patients should theoretically actually WANT it that way. The reason is because it means that insulin makers would be forced to innovate in order to make vastly better insulins (rather than merely incrementally better ones like those we ' ve seen in recent years; such as Novolog/aspart toFasterInsulinAspart, [a.k.a. Fiasp]), and we should want better insulins because every insulin analogue we have today all retain a nasty efficacy failure known as hypoglycemia. Instead, what if big insulin finally fixed that not-so-little problem? If they fixed the problem of hypoglycemia, then you might expect (and maybe even bewilling) to pay a little more for fixing that problem. We may finally potentially be headed in that direction. It ' s just that we ' ve grown too accustomed to paying ridiculous prices for the same $#!tty old insulins.If you ignore the hy...
Source: Scott's Web Log - Category: Endocrinology Tags: glucose responsive insulin 2023 Amphastar Biocon bloomberg BusinessWeek Civica insulin prices Lannett Sandoz the Business of Diabetes Source Type: blogs